PUR 1800

Drug Profile

PUR 1800

Alternative Names: PUR-1800

Latest Information Update: 09 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator RespiVert
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease

Most Recent Events

  • 13 Mar 2018 Pulmatrix intends to complete chemistry, manufacturing and control development work and 28-day GLP inhalation toxicology studies in 2018
  • 13 Mar 2018 Pulmatrix plans a phase IIa proof-of-principle trial for Chronic obstructive pulmonary disease in unknown countries in 2019
  • 04 Aug 2017 RespiVert completes a proof-of-concept study in Chronic obstructive pulmonary disease before June 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top